Leukemia Treatment Options

• Leukemia treatment is chosen based on the specific type and subtype of leukemia, its genetic features, how far the disease has progressed, and the patient’s overall health.
• The main treatment categories are chemotherapy, radiation therapy, targeted therapy, immunotherapy, and stem cell transplant, often combined depending on the case.
• Targeted drugs called tyrosine kinase inhibitors changed the outlook for chronic myeloid leukemia by blocking the abnormal protein made by that disease’s characteristic gene change.
• CAR T-cell therapy, which re-engineers a patient’s own immune cells to attack leukemia cells, is now approved for certain aggressive forms of the disease.
• Because leukemia treatments can affect healthy blood cells as well as cancerous ones, supportive care and side-effect management are an ongoing part of the treatment plan.

Understanding Your Leukemia Treatment Options

Leukemia is actually a group of related cancers that start in blood-forming tissue, most often the bone marrow, rather than a single disease, and the specific type a person has shapes nearly every treatment decision that follows. Treatment is tailored to the type of leukemia — acute myeloid leukemia, for example, behaves very differently from chronic lymphocytic leukemia — along with its genetic and molecular features, how advanced the disease is, and the patient’s age, general health, and preferences. A care team, typically including an oncologist or hematologist, reviews these factors together to recommend a plan, and getting a second opinion before starting treatment is common and reasonable.

Diagnosis usually combines blood tests, a bone marrow biopsy, and genetic or molecular testing to pin down the exact type and subtype of leukemia, since that detail can change which drugs are likely to work. From there, treatment goals range from an intensive approach aimed at remission and long-term disease control to a lower-intensity strategy focused on symptoms and quality of life — an approach used more often in chronic leukemias or in patients who are older or in poorer overall health.

Key Leukemia Treatment Modalities

Several standard treatment categories are used across the different types of leukemia, often in combination rather than alone, with the goal of clearing leukemia cells while limiting harm to healthy tissue.

Chemotherapy and Radiation Therapy

Chemotherapy uses drugs that kill rapidly dividing cells and remains a backbone of leukemia treatment. It is usually given systemically — by mouth or into a vein — so the drugs travel throughout the body; when leukemia cells have reached the brain or spinal cord, chemotherapy can also be delivered directly into the cerebrospinal fluid, an approach called intrathecal chemotherapy, because standard doses given elsewhere in the body do not reach that space well. Which drugs are used, and for how long, depends on the specific type of leukemia being treated. Chemotherapy affects normal blood-forming cells along with cancerous ones, which is why blood counts are watched closely throughout treatment.

Radiation therapy uses high-energy beams to destroy cancer cells or stop them from growing. It is used less often than chemotherapy for leukemia, but it can target a specific area where leukemia cells have collected, such as the brain, or be delivered to the whole body — total body irradiation — as part of preparing a patient for a stem cell transplant, where it helps clear remaining leukemia cells and suppress the immune system so the new cells are not rejected.

Targeted Therapies and Immunotherapy

Targeted therapy uses drugs designed to interfere with specific molecular features of cancer cells rather than attacking all rapidly dividing cells, which can mean fewer effects on healthy tissue. The clearest example is chronic myeloid leukemia, where most patients have a change called the Philadelphia chromosome, which creates an abnormal fusion gene that directs cells to make a protein driving the disease. Drugs known as tyrosine kinase inhibitors, including imatinib, block that protein and have substantially changed outcomes for chronic myeloid leukemia since their introduction. Some targeted drugs are matched to a patient’s leukemia using biomarker testing, which helps predict whether a given drug is likely to help.

Immunotherapy works by helping the immune system recognize and destroy leukemia cells, rather than attacking the cells directly with a drug. Some immunotherapy drugs are engineered antibodies that bind to specific proteins on leukemia cells, marking them for destruction by the immune system or delivering a toxic payload directly to the cell; these are used for certain leukemia types, including some cases that have come back after earlier treatment. CAR T-cell therapy, described below, is a more specialized form of immunotherapy that goes a step further by re-engineering a patient’s own immune cells.

Innovations in Leukemia Treatment

Research has added new tools to the standard treatments described above, particularly for leukemias that are aggressive or have not responded to earlier therapy.

CAR T-Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy is a specialized immunotherapy used for certain aggressive leukemias, including some cases of B-cell acute lymphoblastic leukemia that have not responded to other treatment or have come back. In this procedure, immune cells called T-cells are drawn from the patient’s own blood, then reprogrammed in a laboratory so they carry a receptor able to latch onto a target found on leukemia cells; large numbers of these modified cells are multiplied and returned to the patient through an infusion, where they can hunt down and destroy cells bearing that marker. The Food and Drug Administration has approved several CAR T-cell products for use in specific leukemias and other blood cancers, and doctors reserve the treatment for patients who meet the criteria for a given product.

Precision Medicine and Clinical Trials

Precision medicine uses information about the genetic changes driving an individual patient’s leukemia to help guide treatment choices, rather than relying on a single standard regimen for everyone with the same diagnosis. Biomarker and cytogenetic testing — looking for chromosome changes such as the Philadelphia chromosome — is part of this approach and can influence which targeted therapy, if any, is likely to help.

Clinical trials test new drugs, new combinations of existing treatments, and new approaches to earlier steps such as diagnosis or supportive care. Taking part in a trial can give a patient access to treatment not yet widely available, and the National Cancer Institute maintains a searchable database of trials open to new patients, organized by cancer type, patient age, and location.

Managing Side Effects of Leukemia Treatments

Because leukemia treatments work by killing rapidly dividing cells, they can also affect healthy, fast-growing cells elsewhere in the body, including the cells that make blood. Managing these effects, and the supportive care that goes with them, is its own extensive topic; the summary below covers only the basics of what to expect.

Common Side Effects and Their Management

Depending on the treatment used, patients may experience fatigue, nausea, hair loss, mouth sores, or a reduced ability to fight infection, since chemotherapy also lowers healthy white blood cell counts. Care teams monitor blood counts closely and adjust supportive treatment as needed throughout therapy; the specifics of individual side effects and how each is managed are addressed separately as part of ongoing supportive care planning.

Supportive Care During Treatment

Alongside treatments aimed directly at leukemia cells, supportive care — such as transfusions, infection prevention, and nutritional support — helps patients tolerate treatment and stay as well as possible while it continues. This is coordinated by the treatment team and adjusted to each patient’s needs over the course of care.

Frequently Asked Questions

How long does leukemia treatment typically last?

There is no single answer — it depends on the type of leukemia and how the disease responds. Acute leukemias generally start with an intensive remission-induction phase followed by a consolidation phase to clear any remaining leukemia cells, together often lasting several months. Chronic leukemias may involve treatment that continues over a longer period, or watchful monitoring with treatment started only if the disease becomes active. Your care team can give you a timeline specific to your diagnosis and response to treatment.

What is the role of stem cell transplant in leukemia treatment?

A stem cell transplant, also called a bone marrow transplant, replaces blood-forming cells destroyed by the high-dose chemotherapy or radiation used to eliminate leukemia cells. The replacement cells usually come from a donor — an allogeneic transplant — or, less commonly for leukemia, from the patient’s own cells collected and stored beforehand, called an autologous transplant. With a donor transplant, the new immune cells can also help attack any leukemia cells that remain, an effect that adds to the transplant’s benefit. It is generally used for certain acute leukemias and higher-risk or recurrent disease, once other treatment has prepared the way for it.

Are there different treatment approaches for acute versus chronic leukemia?

Yes. Acute leukemias, such as acute myeloid leukemia and acute lymphoblastic leukemia, usually need treatment to start soon after diagnosis, typically intensive chemotherapy aimed at remission and sometimes followed by a stem cell transplant. Chronic leukemias progress more slowly: chronic myeloid leukemia is generally treated with a long-term targeted drug that blocks the abnormal protein driving the disease, while chronic lymphocytic leukemia may first be watched closely, with treatment started only once the disease becomes active or causes symptoms.

Sources

• National Cancer Institute – Acute Myeloid Leukemia Treatment (PDQ®) – Patient Version
• National Cancer Institute – Chronic Myeloid Leukemia Treatment (PDQ®) – Patient Version
• National Cancer Institute – Acute Lymphoblastic Leukemia Treatment (PDQ®) – Patient Version
• National Cancer Institute – Stem Cell Transplants for Cancer